Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS

Inclusion Criteria:

Ability to provide informed consent
Stated willingness to comply with all study procedures and availability for the duration of the study

Any of the following:

Patients with a new diagnosis of AML, ALL, high risk myelodysplastic syndrome (MDS), or high risk chronic myelomonocytic leukemia (CMML) who are age 65 and older.

OR

Patients with relapsed AML, ALL, high risk MDS or high risk CMML, ages 18 and older.

OR

Patients with refractory AML, ALL, high risk MDS or high risk CMML, ages 18 and older.

Refractory AML/ALL will be defined as persistent leukemia despite two or more cycles of induction chemotherapy.

Refractory MDS will be defined according to the 2006 IWG response criteria Refractory CMML will be based on the assessment of the treating investigator.

Exclusion Criteria:

1. Participants must not have a diagnosis of Acute Promyelocytic Leukemia (APL)